InMed Pharmaceuticals Inc. (INM): Cash & Equivalents
$11.08M
As of 2025-06-30
+21.5%
3-year compound annual growth
+13.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $11.08M | +68.5% | 2025-09-23, Balance as of period end |
| 2024-06-30 | $6.57M | -26.3% | 2025-09-23, Balance as of period end |
| 2023-06-30 | $8.91M | +44.3% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $6.18M | -16.1% | 2023-09-29, Balance as of period end |
| 2021-06-30 | $7.36M | +26.8% | 2022-09-23, Balance as of period end |
| 2020-06-30 | $5.81M | n/a | 2021-09-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | 2025-06-30 | $11.08M | +68.5% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.39M | +26.9% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $2.18M | -59.8% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $600.0K | n/a |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $1.11M | -27.9% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $2.38M | -57.6% |
Compare INM, TCRT, ATXI, NTHI side by side · Screen every company in Pharmaceutical Preparations ↗